It is known that APOE ε4 drives the production of Aβ, the accumulation of Aβ fibrils in AD patients [37], exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy [62] and affects CSF αSyn levels in the prodromal phase of sporadic and familial AD [67]. This evidence concerns the gene MAPT and Alzheimer disease.